Clinical trials: Skin Infection
Onychomycosis
Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis
Single-center study, single blind, comparative with the objective of evaluating the efficacy and safety of an investigational product as an adjunct in the treatment of onychomycosis improvement of 90 days ± 2 days.
- Trial name
- NCT02961634
- Testing
- Nailner 2 in 1, Ciclopirox 8%
- Volunteers
- 46 people
- Sponsor
- MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA
Infected Toenails, Onychomycosis
PinPointe FootLaser for the Treatment of Onychomycosis
To evaluate the safety and efficacy of the PathoLase FootLaser treatment of infected toenails.
- Trial name
- NCT00935649
- Testing
- PinPointe FootLaser
- Where
- 4 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- PathoLase, Inc.
Squamous Cell Carcinoma of the Oral Cavity, Leukoplakia Oral
Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity
Recent studies estimated that 15 to 20% of all cancers in humans are associated with viruses. Among oral cancer about 90% are oral squamous cell carcinomas (OSCC).
- Trial name
- INECOC (NCT01636544)
- Testing
- contralateral healthy tissue biopsy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Pasteur
Staphylococcal Skin Infection
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
- Trial name
- NCT00442832
- Testing
- TD-1792, Vancomycin
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Infections, Gram-Positive Bacterial, Abscess
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria.
- Conditions
- Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis
- Trial name
- FAST (NCT00061633)
- Testing
- Telavancin, Vancomycin or antistaphylococcal penicillin
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Cumberland Pharmaceuticals
Laceration of Skin, Injury Skin
Assessment of DAFILON® Suture Material for Skin Closure
In this non-interventional study (NIS) a polyamide non-absorbable suture (Dafilon®) will be evaluated for skin closure in adult and pediatric patients.
- Trial name
- SKINDA (NCT04617041)
- Where
- 2 sites in Germany, Spain
- Volunteers
- 115 people
- Sponsor
- Aesculap AG
Common Wart
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.
- Trial name
- NCT01796795
- Testing
- Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM
- Volunteers
- 102 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Onychomycosis
Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis
Evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline.
- Trial name
- NCT05560841
- Testing
- topical treatment
- Where
- 2 sites in Tunisia
- Volunteers
- 50 people
- Sponsor
- Karo Pharma AB
Hidradenitis Suppurativa
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
- Trial name
- NCT04493502
- Testing
- LY3041658
- Where
- 20 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Acute Bacterial Skin and Skin Structure Infections
Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
This is a phase III, multi-center, randomized, active-comparator, study in subjects with ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and IV subgroup 2.
- Trial name
- NCT03405064
- Testing
- Oral Levonadifloxacin/Linezolid Tablet, Intravenous Levonadifloxacin/Linezolid Infusion
- Where
- 32 sites in India
- Volunteers
- 501 people
- Sponsor
- Wockhardt
Sarcoma, Kaposi, HIV Infections
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
- Trial name
- NCT00002226
- Testing
- SU5416
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Solid Tumors, Mycosis Fungoides
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma
- Trial name
- NCT02890368
- Testing
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer
Infection, Soft Tissue, Infection, Wound
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
This study focuses on a new drug delivery system (Direct Antibiotic Delivery) to treat soft tissue infections. In this study, cefazolin is delivered directly to the target tissues using subcutaneous injection of antibiotic…
- Conditions
- Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
- Trial name
- DAD (NCT01238276)
- Testing
- Cefazolin, Silberg Tissue Preparation System
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sonescence, Inc.
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Molluscum Contagiosum
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when…
- Trial name
- NCT03186378
- Testing
- VP-102 with applicator
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Verrica Pharmaceuticals Inc.
Skin Diseases, Infectious, Skin Diseases, Bacterial
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.
- Trial name
- NCT00761215
- Testing
- TR-701 200 mg, TR-701 300 mg, TR-701 400 mg
- Where
- 12 sites in United States
- Volunteers
- 192 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hidradenitis Suppurativa
Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting
This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting.
- Trial name
- HARMONY (NCT02786576)
- Where
- 83 sites in Austria, Belgium and 11 more
- Volunteers
- 236 people
- Sponsor
- AbbVie
Juvenile Idiopathic Arthritis
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
- Trial name
- NCT03769558
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- Bristol-Myers Squibb
Genital Warts
Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts
The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.
- Trial name
- NCT00499967
- Testing
- GS-9191 ointment, GS-9191
- Where
- 25 sites in United States
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences